drugset / Trial / NCT01226511

A Study in Pediatric Participants With Generalized Anxiety Disorder

NCT01226511

Phase 3 Completed 281 enrolled Eli Lilly and Company
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to find out if duloxetine \[30-120 milligrams (mg)\] given once a day by mouth for 10 weeks to children and adolescents, is better than placebo when treating Generalized Anxiety Disorder (GAD).

Timeline

Start
2011-06
Primary completion
2013-02
Completion
2013-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Duloxetine Small molecule 30 mg Oral
Subject Duloxetine Small molecule 120 mg Oral

Indications